Hans-Christian Kolberg, MD: The Importance of Reporting Data on Biosimilar Trastuzumab
June 6th 2019Hans-Christian Kolberg, MD, head of the department of obstetrics and gynecology, breast cancer center, and gynecologic cancer center at Marienhospital Bottrop, Germany, reflects on the importance of reporting new cardiac data from the LILAC trial of ABP 980, a trastuzumab biosimilar.
Kalveer Flora, MPharm: Patient Response to Switching to Biosimilar Adalimumab
June 3rd 2019Kalveer Flora, MPharm, London North West University Healthcare National Health Service Trust, discusses how patients have reacted to being switched to biosimilar adalimumab and how they have been supported in the switching process.
Lee Schwartzberg, MD, FACP: Biosimilars and Neutropenia
April 17th 2019Lee Schwartzberg, MD, FACP, medical director and senior partner at The West Clinic, discusses his research that showed that the incidence of febrile neutropenia was similar between patients who received reference filgrastim versus those who received a biosimilar.